ReviewEndocrine oncology (Bristol, England)2025
Overview of management and therapeutic advances in medullary thyroid cancer.
Review in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Beyond Tumor Diameter: Exploratory Cohort-Derived Calcitonin Secretory Categories and Invasive Pathology in Medullary Thyroid Carcinoma.Current oncology (Toronto, Ont.) · 2026Article
- Data Harmonization for Collaborative Research Among Australian and US Registries: A Case Study in Medullary Thyroid Cancer (MTC).World journal of surgery · 2026Article
- Review
- Diagnostic value of calcitonin for lateral cervical lymph node metastasis in medullary thyroid carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Review
- Article
- Diagnostic advances in medullary thyroid carcinoma.Endocrine oncology (Bristol, England) · 2025Article
- Recent advances in applications of artificial intelligence-assisted Raman spectroscopy in diagnosis of cancers.Frontiers in molecular biosciences · 2025Review
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medullary thyroid carcinoma (MTC) is a rare cancer of the thyroid's calcitonin-producing C cells. This review covers recent advances in MTC treatment, emphasizing surgical and systemic therapies. For localized MTC, surgery remains the primary and most effective treatment, with total thyroidectomy and lymph node dissection providing the highest potential for cure. However, prognosis worsens significantly with local and distant metastases, underscoring the importance of early diagnosis and intervention. MTC can be sporadic or hereditary, with the latter associated with germline
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.